Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Germ”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03363217
What this trial is testing

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Who this might be right for
Low-grade GliomaPlexiform NeurofibromaCentral Nervous System Glioma
St. Justine's Hospital 114
Early research (Phase 1)Study completedNCT00509691
What this trial is testing

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Who this might be right for
Cancer
University of Louisville 20
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)WithdrawnNCT01174537
What this trial is testing

New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma

Who this might be right for
GlioblastomaSarcomaNeuroblastoma
Hadassah Medical Organization
Early research (Phase 1)UnknownNCT03903458
What this trial is testing

Tinostamustine and Nivolumab in Advanced Melanoma

Who this might be right for
Malignant Melanoma
Markus Joerger 21
Early research (Phase 1)Looking for participantsNCT06660420
What this trial is testing

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

Who this might be right for
Phase 1Recurrent MelanomaRefractory Melanoma
M.D. Anderson Cancer Center 39
Early research (Phase 1)Looking for participantsNCT07358260
What this trial is testing

B7-H3.CD28Z.CART in Solid Tumors

Who this might be right for
Pediatric Solid TumorNeuroblastoma
Robbie Majzner 40
Testing effectiveness (Phase 2)Ended earlyNCT03901573
What this trial is testing

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Who this might be right for
MelanomaMerkel Cell CarcinomaCutaneous Squamous Cell Carcinoma
NeoImmuneTech 31
Early research (Phase 1)Ended earlyNCT02536183
What this trial is testing

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

Who this might be right for
Pediatric CancerSolid TumorsRhabdomyosarcoma+7 more
AeRang Kim 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT03363373
What this trial is testing

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Who this might be right for
Neuroblastoma
Y-mAbs Therapeutics 122
Early research (Phase 1)Active Not RecruitingNCT03618381
What this trial is testing

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Who this might be right for
Pediatric Solid TumorGerm Cell TumorRetinoblastoma+13 more
Seattle Children's Hospital 44
Testing effectiveness (Phase 2)Study completedNCT02308527
What this trial is testing

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Who this might be right for
Neuroblastoma
University of Birmingham 225
Testing effectiveness (Phase 2)Study completedNCT05027386
What this trial is testing

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.

Who this might be right for
Neuroblastoma
Sun Yat-sen University 125
Testing effectiveness (Phase 2)Ended earlyNCT00617929
What this trial is testing

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Who this might be right for
Cancer
Masonic Cancer Center, University of Minnesota 12
Early research (Phase 1)Study completedNCT00001573
What this trial is testing

A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy

Who this might be right for
GliomaSarcoma
National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT04119024
What this trial is testing

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more
Anusha Kalbasi 18
Not applicableStudy completedNCT01355679
What this trial is testing

Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma

Who this might be right for
Neuroblastoma
Giselle Sholler 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT05421897
What this trial is testing

Rapid Administration Pilot for Infusing Dinutuximab

Who this might be right for
Neuroblastoma
Children's Hospital Los Angeles 30
Early research (Phase 1)Active Not RecruitingNCT03598244
What this trial is testing

Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Who this might be right for
Recurrent Diffuse Intrinsic Pontine GliomaRecurrent Malignant GliomaRecurrent Medulloblastoma+5 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Study completedNCT01290536
What this trial is testing

Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases

Who this might be right for
Colorectal NeoplasmsNeuroendocrine TumorsCholangiocarcinoma+2 more
Nicholas Fidelman, MD 42
Next Page